Penumbra, Inc. (PEN)
NYSE · Healthcare · Medical Devices
$317.11−0.14%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $12.5B
- P/E (trailing)
- 77.9
- Forward P/E
- 51.7
- 52-week range
- $221.26 – $362.41
- 52-week change
- +24.23%
- EPS (trailing)
- $4.07
- Analyst rating
- 2.7 Hold
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $1.4B (+17.50%)
- Net income
- $178M
- Operating margin
- 13.5%
- Diluted EPS
- $4.52
- Free cash flow
- $175M
From the company’s annual report on SEC EDGAR.
About Penumbra, Inc.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and…
Headquarters: Alameda, United States · 4,700 employees · penumbrainc.com